@article{article_969310, title={Oncologic and functional outcomes of open retropubic vs robot-assisted radical prostatectomy in patients with high risk prostate cancer}, journal={Endoüroloji Bülteni}, volume={13}, pages={38–46}, year={2021}, author={Şendoğan, Furkan and Tuğcu, Volkan and Turan, Turgay and Şahin, Selçuk and Efiloğlu, Özgür and Yıldırım, Asıf}, keywords={Radikal prostatektomi, Robot-yardımlı radikal prostatektomi, Yüksek riskli prostat kanseri, Açık retropubik radikal prostatektomi}, abstract={<p> <b>Objective </b>: The aim of this study is to evaluate oncological and functional outcomes of open radical prostatectomy (ORP) and robot-assisted prostatectomy (RARP) in patients with high-risk prostate cancer. <br /> <b>Material and Methods: </b> In our study, patients with high-risk prostate cancer who underwent 118 ORP and 66 RARP between 2014-2018 have been evaluated retrospectively. Patients with prostate specific antigen (PSA)>20 ng/ml or Gleason score >7 or clinical stage ≥T2c according to D’Amico risk classifications are considered to high-risk prostate cancer. Preoperative abdominal magnetic resonance imaging (MRI) and bone scintigraphy were performed in each patient to assess the risk of extracapsular extension and exclude metastasis. The PSA value of 0.2 ng/mL in patients following two consecutive evaluations is accepted as biochemical recurrence. Urinary continence with pad use and erectile function were evaluated by verbal questioning of vaginal penetration performed with or without the use of phosphodiesterase type-5 inhibitors. <br /> <b>Results </b>: In our study; preoperative PSA values, prostate biopsy ISUP grade, and clinical stage were found significantly higher in the ORP group. There was no significant difference between the groups in terms of positive surgical margin, extracapsular extension, seminal vesicle, and lymph node invasion. Biochemical recurrence was higher in the ORP group but there was no significant difference between the groups in terms of adjuvant treatments such as radiotherapy and androgen deprivation therapy. And there was no significant difference in urinary incontinence and erectile dysfunction in the first-year assessments of patients. Median follow-up was 15.55 and 46.45 months for RARP and ORP, respectively. <br /> <b>Conclusion: </b> ORP and RARP have similar oncological and functional outcomes in high-risk prostate cancer.  <br /> </p>}, number={2}, publisher={Endoüroloji Derneği}, organization={Yok}